Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trialWei Wu, Jieqiong Liu, Yan Nie et al.|BMC Cancer|2021Cited by 14